North America: Expanding highly developed healthcare system
North America leads in the Immunohematology Market Size, accounting for over 85.17% of the global revenue in 2024, driven by a highly developed healthcare system, high blood‑transfusion volumes, and stringent regulatory standards for blood safety. The region has rapid adoption of automated blood‑grouping platforms, molecular diagnostics (PCR, NGS), and integrated digital systems that link blood banks with hospital EMRs and haemovigilance databases.
- The U.S. performs approximately 13.6 million whole blood and red blood cell donations annually, supporting sustained demand for immunohematology testing, transfusion safety protocols, and automated compatibility screening systems.
Ongoing government initiatives, advanced donor‑management infrastructures, and a strong presence of global vendors such as Grifols, Immucor, Abbott, and Thermo Fisher support continuous modernization of transfusion services and drive steady mid‑single‑digit CAGR growth through 2034.
- GE Healthcare continues expanding AI-enabled diagnostic technologies that improve laboratory workflows and support faster interpretation of transfusion-related testing, enhancing blood safety infrastructure across North American healthcare systems.
Europe: Growing immunohematology market
Europe Immunohematology Market size was valued at USD 528.378 million in 2024, making it the second-largest regional market with a 30% share. Europe is a mature but still growing immunohematology market, characterized by centralized national blood services, strong regulatory frameworks under EU directives, and a focus on standardization and haemovigilance. Countries such as Germany, the UK, and France lead adoption, with many transfusion centers operating semi‑automated or fully automated platforms and implementing molecular‑based antigen genotyping for high‑risk patients.
- The European Medicines Agency (EMA) supports advanced therapy and diagnostic evaluation pathways, accelerating adoption of precision diagnostics. Strong regulatory harmonization across Europe supports expansion of standardized immunohematology and blood safety testing systems.
Regional growth is supported by ageing populations, rising incidence of hematologic disorders, and investment in digital health, pushing the European segment to expand at a CAGR of roughly 5–8% over the 2024–2031 horizon, depending on the study.
Asia Pacific: Rising awareness of blood safety
Asia Pacific is the fastest‑growing region in immunohematology, driven by improving healthcare infrastructure, rising awareness of blood safety, and government‑led voluntary‑donation campaigns. Countries such as India, China, Japan, and South Korea are expanding their network of accredited blood banks and central transfusion services, while also investing in automation, EQAS‑linked quality programs, and digital donor registries (for example, India’s e‑Rakt Kosh and Rare Donor Registry).
The APAC market is expected to grow from around USD 660–700 million in 2024–2025 toward USD 1+ billion by the early 2030s, reflecting strong demand for both reagents and next‑generation testing platform.
South America: Protection of largely manual tube‑based
South America’s immunohematology market is mid‑sized and characterized by gradual modernization of public‑sector transfusion services, especially in countries such as Brazil, Argentina, and Chile. These markets are shifting from largely manual tube‑based methods toward semi‑automated platforms and basic molecular screening, supported by national blood‑safety programs and WHO‑aligned standards. Growth is moderate but persistent, reflecting rising demand for oncology, surgical, and trauma care, as well as government efforts to expand voluntary blood‑donation networks and digital tracking systems.
Middle East & Africa: Emerging largely manual tube‑based
The Middle East and Africa represent a smaller but structurally evolving immunohematology market, with growth concentrated in the Gulf Cooperation Council (GCC) countries and selected higher‑income African nations. These regions are adopting modern blood‑banking practices, including basic automation, improved screening for transfusion‑transmitted infections, and participation in regional haemovigilance and quality‑assurance schemes. However, growth is constrained by uneven healthcare funding, limited skilled workforce, and variable regulatory harmonization, which keeps the MEA segment at a lower share and more volatile growth trajectory compared with North America, Europe, and APA reas.
